BioPerfectus Technologies

Bioperfectus Technologies Co., Ltd. is one of the leading molecular diagnostic solution providers in the global in-vi... read more

BioPerfectus Presents Latest Solutions for Women's Health and Infectious Disease Diagnosis

By LabMedica International staff writers
Posted on 05 Feb 2025

Image: The SS-AMS3000 automated reproductive tract microbiota microscopic image analysis system is on display at the show (Photo courtesy of Bioperfectus)

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) is participating in Medlab Middle East 2025 where it is featuring advanced solutions for vaginal microbiota testing and self-sampling for women's health.

Bioperfectus is demonstrating the SS-AMS3000 automated reproductive tract microbiota microscopic image analysis system at the event. This system consists of an optical imaging system (including the light source, automatic platform, objective lens, and lens barrel), an image acquisition system (camera), and software (including control and analysis functions), which need to be used with a computer. The system’s operating principle is to magnify and capture images of reproductive tract samples on slides for user observation. It also enables the analysis of cells and microorganisms in microscopic images. Alongside, Bioperfectus is highlighting the SDA-90 automated stainer which is used for staining treatment of blood and other body fluids before sample analysis. It integrates new technologies such as machinery, electricity, and computer software to achieve fully automatic staining of samples. The SDA-90 automated stainer is used together with the stain reagents produced by BioPerfectus for staining of blood and other body fluids before sample analysis. It can be connected with the BioPerfectus Biological Automatic Microscope to realize fully automatic assembly line detection of vaginal microecological morphology.

BioPerfectus is also showcasing its comprehensive solution for cervical cancer screening, aiming to accelerate the global elimination of cervical cancer. This solution has tested over 10 million women, covering over 60 countries and regions worldwide. It can be customized to meet various application scenarios. The Quantitative HPV Genotyping Detection, designed for single-visit screening and optimization of HPV testing triage, brings higher cost efficiency. The 16+2 high-risk testing option caters to large-scale population screening. Integration with internet hospitals and self-sampling testing facilitates at-home testing, enhancing convenience and expanding the coverage of screening.